ネブラスカ州におけるがん（全種類）の臨床試験
ネブラスカ州内の拠点で、がん（全種類）に関する22件の研究が参加者を募集しています。
ネブラスカ州内の都市
公式研究テキスト（英語）
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Nho - Revive Research Institute /ID# 277569, Lincoln
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07155187A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- Mary Lanning Healthcare ( Site 0019), Hastings
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06979596A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06989437A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- University of Nebraska Medical Center, Omaha
- Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06901531TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Nebraska Medical Center, Omaha
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University Of Nebraska Medical Center, Omaha
被験者募集中第2/3相
全年齢 · 全性別 · 2026/09/18更新 · NCT03435796RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Nebraska Medical Center, Omaha
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07002034Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Nebraska Cancer Specialists, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07660055Project: Every Child for Younger Patients With Cancer
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Saint Francis, Grand Island
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT04198766A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- NHO Revive Research Institute, LLC /ID# 267869, Lincoln
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT05650632Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Nebraska Cancer Specialist, Grand Island
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/30更新 · NCT06162221Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
被験者募集中
18歳〜75歳 · 全性別 · 2026/06/17更新 · NCT05486572A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Nho - Revive Research Institute /ID# 276115, Lincoln
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/06/08更新 · NCT07005102CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Fred and Pamela Buffett Cancer Center, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078GEMINI-NSCLC: NSCLC Biomarker Study
- Nebraska Cancer Specialists, Omaha
被験者募集中観察研究
18歳以上 · 全性別 · 2026/02/05更新 · NCT05236114SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- University of Nebraska Medical Center, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/05/18更新 · NCT05970497Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Nebraska Cancer Specialists, Omaha
被験者募集中観察研究
18歳以上 · 全性別 · 2025/05/06更新 · NCT05234177Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Nebraska Medicine - Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medicine, Omaha
被験者募集中
18歳以上 · 全性別 · 2024/11/27更新 · NCT03860883ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。